What biomedical equipment services does Oregon Biomedical Services provide?

We provide preventive maintenance, corrective repair, calibration, electrical safety inspection, and isolated power system (IPS) testing for hospitals, surgery centers, and clinics.

Are your biomedical technicians certified?

Yes. Our BMETs are certified and our work follows Joint Commission, CMS, and NFPA 99 standards so your facility stays survey-ready.

How fast can you respond to an equipment failure?

We offer scheduled preventive maintenance plus priority on-call service to minimize downtime on critical medical equipment.

Do you help with regulatory compliance and documentation?

We do. Every service includes the documentation you need for Joint Commission, CMS, and NFPA 99 surveys.

How do I request service or a quote?

Call (424) 204-2382 or email info@oregonbiomedicalservices.com and our team will schedule an assessment.

Oregon Biomedical Services | Medical Equipment Repair & Field Service

Medical equipment repair and field service — for Oregon hospitals and health systems.

Oregon Biomedical Services keeps clinical equipment ready and compliant across Portland, the Willamette Valley, and statewide. We repair, calibrate, and preventively maintain every modality — biomedical, medical imaging, and scientific laboratory — and build custom maintenance programs that maximize uptime while reducing cost.

Educational

NFPA 99 2026 Piped Gas Testing Expansion: OHA Compliance Checklist for Oregon Hospitals

The 2026 edition of NFPA 99, the Health Care Facilities Code, continues to organize requirements around a risk-based framework in which the level of testing, documentation, and redundancy scales with the clinical consequence of a system failure. For Oregon hospitals, the categories that draw the most survey attention remain medical gas and vacuum systems, electrical distribution, and the isolated power and line isolation monitoring that protect wet procedure locations. Facilities should confirm which edition their Authority Having Jurisdiction and CMS Conditions of Participation currently enforce, since adoption of a new code edition is not automatic and often lags publication.

Practical readiness work centers on the records surveyors ask to see: current inventories of medical gas outlets and zone valves, verification and cross-connection test reports after any system alteration, periodic testing of line isolation monitors, and calibration traceability for the test equipment itself. Wet procedure locations such as operating rooms generally require either isolated power or ground-fault protection, and the governing body must document the risk assessment behind that choice. Keeping this documentation continuously audit-ready — rather than reconstructing it before a survey — is the single most reliable way to avoid findings.

Because code-adoption timelines and enforcement details differ by facility and jurisdiction, hospitals should verify specific effective dates and testing intervals against the published NFPA 99 text and their state and accreditation requirements rather than relying on summaries.

Sources: NFPA 99 (Health Care Facilities Code); Centers for Medicare & Medicaid Services; The Joint Commission

May 9, 202612 min read

Informative

FDA-CMS RAPID Pathway: Fast-Track Coverage for Breakthrough Devices Reaches Oregon

Coordinating device clearance with insurance coverage has long been a gap in the U.S. system: a device can earn FDA marketing authorization years before Medicare decides whether and how to pay for it. The FDA reviews a device for safety and effectiveness, while CMS separately determines whether an item is reasonable and necessary for coverage. When those processes are not aligned, hospitals can face equipment that is approved but not yet reimbursed, complicating capital and service-planning decisions.

Efforts to shorten that lag — including pathways tied to the FDA's Breakthrough Devices Program and CMS coverage frameworks — aim to give Medicare beneficiaries earlier, more predictable access to novel diagnostics and therapeutics. For Oregon facilities in Portland, Salem, and Eugene, earlier adoption of advanced modalities also raises the operational stakes: new devices require trained biomedical staff, spare-parts strategies, calibration and preventive-maintenance protocols, and documentation ready for accreditation surveys before the first patient is scanned or treated.

Coverage rules, effective dates, and eligibility criteria for any expedited pathway change over time and can vary by device class, so hospitals should confirm current policy directly with the FDA and CMS rather than relying on secondhand timelines.

Sources: U.S. Food and Drug Administration; Centers for Medicare & Medicaid Services

May 16, 20267 min read

Field Notes

Slug in the Analyzer: A Portland Lab Incident Report

"A Pacific banana slug had made its home in the histology analyzer's moisturized chamber. It was a sign of the facility's beautiful location and our need for better equipment enclosures. The slug was safely relocated to the garden. The chamber was cleaned and sealed."

The lighthearted story points at a serious maintenance principle: environmental control matters as much as the instrument itself. Laboratory analyzers are sensitive to humidity, temperature, dust, and pest intrusion, and manufacturers specify ambient operating conditions precisely because deviations can skew results or damage optics and fluidics. A warm, moist internal chamber is exactly the kind of microenvironment that invites contamination, which is why clinical laboratories build environmental monitoring, sealed enclosures, and routine cleaning into their quality programs.

For a biomedical service team, incidents like this reinforce the value of preventive maintenance visits that inspect seals, filters, and gaskets before a small ingress becomes a costly failure or a compromised patient result. Well-documented environmental controls and equipment maintenance also support the laboratory quality-system expectations that accreditation and CMS CLIA oversight are built around.

Sources: U.S. Food and Drug Administration; CMS — Clinical Laboratory Improvement Amendments (CLIA)

May 24, 20264 min read